PopulationsHumans
Experimental and real‐world evidence supporting the repurposing of drugs targeting proteotoxicity and inflammation to treat Alzheimer's disease
AAIC 2025 Abstract
Abstract
Background: Alzheimer's Disease and Related Dementia (ADRD) affects 10.9% of people above 65 years old in the US. Disease modifying and symptomatic therapies for ADRD have marginal clinical value; thus finding effective treatments is paramount.
The paper
Icahn School of Medicine at Mount Sinai
AAIC 2025 Abstract · 23 Dec 2025 · CC BY
Presented at AAIC 2025
